Advertisement

ePS3.10 Patient demographics and baseline disease characteristics in a multicentre, randomised, double-blind, placebo-controlled phase 2b study of lenabasum, a selective cannabinoid receptor type 2 agonist, in cystic fibrosis

      This paper is only available as a PDF. To read, Please Download here.